Clinical Trial Update: Immunogenicity and Safety Study of NBP606 in Healthy Infants [Phase 3]

View source ↗

Summary

Phase 3 immunogenicity and safety study of NBP606 in healthy infants completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• NBP606

Snippet

Sponsor: SK Chemicals Co., Ltd. | Conditions: Pneumococcal Infections | Phase 3 | Status: COMPLETED